Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 6;22(4):293-299.
doi: 10.4274/jtgga.galenos.2020.2020.0110. Epub 2021 Jan 4.

The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation

Gülşen Doğan Durdağ  1 , Gizem Bektaş  2 , Esengül Türkyılmaz  3 , Halime Göktepe  4 , Meltem Sönmezer  5 , Yavuz Emre Şükür  6 , Batuhan Özmen  6 , Cem Atabekoğlu  6 , Bülent Berker  6 , Ruşen Aytaç  6 , Murat Sönmezer  6
Affiliations

The efficacy of dydrogesterone use to suppress premature luteinizing hormone surge on cycle outcomes in controlled ovarian stimulation

Gülşen Doğan Durdağ et al. J Turk Ger Gynecol Assoc. .

Abstract

Objective: Progestins are used as an alternative to gonadotropin releasing hormone (GnRH) antagonists to suppress premature luteinizing hormone (LH) surge and a flexible protocol has been defined recently. The aim of this study was to compare the efficacy of flexible protocols with dydrogesterone and GnRH antagonist in suppressing LH surge.

Material and methods: This retrospective, case-control study, was conducted in an infertility unit of a tertiary university hospital. A daily dose of 40 mg dydrogesterone was compared with GnRH antagonist (GnRHant) in controlled ovarian hyperstimulation cycles between July 2018 and July 2019. Dydrogesterone was started when the leading follicle was 12 mm or serum estradiol was over 300 pg/mL. A subgroup analysis of poor responder patients was also performed.

Results: In total there were 105 subjects aged between 23 and 41 years, 52 in the dydrogesterone group and 53 in the GnRHant group. Duration of pituitary suppression was longer in dydrogesterone group. Premature ovulation was observed in 11.5% (6/52) and 0% in the dydrogesterone and GnRHant groups, respectively. However, collected oocyte counts and metaphase II oocyte counts were found to be similar between the groups. The six patients with premature ovulation were in poor responder subgroup.

Conclusion: Dydrogesterone can be used as an alternative to antagonist regimen in patients where embryo transfer is not planned in the same cycle. However, flexible regimen may not be appropriate in patients with diminished ovarian reserve, as advanced follicular maturation and delayed suppressive effect of oral progesterone may cause premature ovulation. Randomized controlled trials in particular patient groups are required to determine the most effective minimum dose and time of application to ensure treatment success.

Keywords: Controlled ovarian hyperstimulation; dydrogesterone; luteinizing hormone surge; progestin-primed ovarian stimulation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflict of interest is declared by the authors.

Figures

Figure 1
Figure 1
(a) Regular PPOS protocol, (b) Flexible PPOS protocol PPOs: Progestin-primed ovarian stimulation
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104:62–70. - PubMed
    1. Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017;23:211–20. - PubMed
    1. Wang Y, Kuang Y, Chen Q, Cai R. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial. Trials. 2018;19:455. - PMC - PubMed
    1. Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018;33:229–37. - PubMed
    1. Chen YM, Qi QR, Xie QZ, Yang YF, Xia Y, Zhou XD. Effect of progestin-primed ovarian stimulation protocol on outcomes of aged infertile women who failed to get pregnant in the first IVF/ ICSI Cycle: A self-controlled study. Curr Med Sci. 2018;38:513–8. - PubMed

LinkOut - more resources